Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

Discover how Group Captain Sanjeev Kumar Mittal transformed Narayana Nethralaya into a leading healthcare institution through strategic leadership and ethical governance.

Forward Therapeutics, Inc ('Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that the first participants have been dosed in ...

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is gen ...

B ryan Follicle, Thought Leader, Serial Founder, Dad, Husband, Son: Don’t let anyone tell you that your dreams are ...

Hong Kong’s privacy watchdog has asked LinkedIn users to review their privacy settings. According to reports, the ...

Market is projected to grow from USD 449.83 billion in 2024 to USD 28560 billion by 2035, registering an impressive CAGR of ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

Foodtech major Swiggy reported yet another quarter of loss in Q2, with its quick commerce arm Instamart continuing to be the ...

Artificial intelligence does not merely generate content. It optimizes it for emotional impact. Through semantic and ...

If you’ve noticed changes in your LinkedIn post performance, a major factor is LinkedIn’s new AI system, 360Brew, which ...